Compare EHTH & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHTH | JSPR |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 26.3M |
| IPO Year | 2006 | 2019 |
| Metric | EHTH | JSPR |
|---|---|---|
| Price | $0.58 | $0.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $1.81 | ★ $8.33 |
| AVG Volume (30 Days) | 350.8K | ★ 360.5K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,395,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 45.86 | N/A |
| 52 Week Low | $0.59 | $0.32 |
| 52 Week High | $5.89 | $2.69 |
| Indicator | EHTH | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 23.62 | 36.56 |
| Support Level | N/A | $0.42 |
| Resistance Level | $0.77 | $0.67 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.05 | 15.15 |
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is derived from the United States. It also has a presence in China.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.